Carmen Blanco Abad

Dr. Carmen Blanco Abad

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2026 in ESMO Open
Verified
Journal Article
Open access
ETEduardo Terán
Eduardo Terán
Roberto Pazo-CidRoberto Pazo-Cid
Roberto Pazo-Cid
LCL. Caritá
L. Caritá
MAMaría Alsina
María Alsina
CHC. Hierro
C. Hierro
TMT. Macarulla
T. Macarulla
Claudin 18.2 (CLDN18.2) is highly expressed in up to 40% of gastroesophageal adenocarcinomas (GEA) and represents an emerging therapeutic target for these tumors. However, its distribution across molecular subtypes and its prognostic and predictive roles remain insufficiently studied. This ambispective, multicenter study included 563 patients with GEA diagnosed between 2019 and 2025 across 17 European institutions. Tumor samples were analyzed for CLDN18.2, human epidermal growth factor receptor 2 (HER2), mismatch repair, Epstein-Barr virus (EBV), and programmed death-ligand 1 [PD-L1; combined positive score (CPS)] using immunohistochemistry and/or in situ hybridization. Molecular alterations were characterized using next-generation sequencing. Associations between molecular features and clinical outcomes, such as overall response rate (ORR), median progression-free survival (mPFS), and median overall survival (mOS), were evaluated. High CLDN18.2 expression was observed in 48.3% of tumors, correlating with diffuse-type histology and peritoneal involvement (P < 0.01). Its prevalence varied across molecular subtypes: 33.9% in deficient mismatch repair, 62.5% in EBV-positive, 41.9% in HER2-positive tumors, and 47.2% in tumors with PD-L1 CPS ≥5. Among patients treated with first-line chemotherapy, CLDN18.2 status did not affect mPFS [hazard ratio (HR) 0.90; P = 0.50] or mOS (HR 1.06; P = 0.80). However, among HER2-positive patients, CLDN18.2-high tumors were associated with improved outcomes with HER2-targeted therapy (mPFS 17.0 versus 8.9 months, HR 0.42; P = 0.03; mOS 43.0 versus 23.0 months, HR 0.40; P = 0.07). By contrast, in patients with CLDN18.2-high tumors receiving an immunotherapy-based regimen (IO), there was a trend toward lower ORR (51% versus 64%; P = 0.15), shorter mPFS (8.9 versus 14.0 months; HR 1.47; P = 0.14), and reduced mOS (16.0 versus 43.0 months; HR 2.04; P = 0.052). Combined analyses of CLDN18.2 and PD-L1 showed poorer survival outcomes in CLDN18.2-high tumors across PD-L1 thresholds. CLDN18.2-high GEA was more prevalent than previously reported in pivotal trials and showed substantial overlap across molecular subtypes. It was associated with a greater benefit from HER2-targeted therapy but a trend toward poorer outcomes with IO, underscoring the need for biomarker-guided therapeutic strategies in GEA.

9 January 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
CACarmen Blanco Abad
Carmen Blanco Abad
PPPaula Gomila Pons
Paula Gomila Pons
SRSara Elena Campos Ramírez
Sara Elena Campos Ramírez
MAMaría Álvarez Alejandro
María Álvarez Alejandro
MRMaría Irene Torres Ramón
María Irene Torres Ramón
Roberto Pazo-CidRoberto Pazo-Cid
Roberto Pazo-Cid
Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with a five-year survival rate of approximately 13% for advanced stages. While the majority of PDAC cases are sporadic, a significant subset is attributable to hereditary and familial predispositions, accounting for approximately 25% of cases. This article synthesizes recent advancements in the understanding, detection, and management of hereditary pancreatic cancer (PC). Results: Our review highlights the critical role of genetic testing (GT) in identifying high-risk individuals (HRIs), with germline pathogenic variants (PVs) found in up to 20% of hereditary PDAC cases. Since the implementation of next-generation sequencing (NGS) panels in 2014, detection capabilities have been significantly enhanced. HRIs can be included in screening programs that facilitate the early detection of PDAC. Early detection strategies, including the use of microribonucleic acid (miRNAs) signatures and novel imaging techniques like hyperpolarized 13C-magnetic resonance spectroscopy (MRS) have shown promising results. The identification of germline pathogenic variants (PVs) or mutations in homologous recombination (HR) genes plays a predictive role in the response to various treatments, prolonging patient survival. Discussion: Universal germline testing for PDAC, as recommended by the National Comprehensive Cancer Network (NCCN), is now a standard practice, facilitating the identification of at-risk individuals and enabling targeted surveillance and intervention. Multidisciplinary management, integrating genetic counseling, imaging, and gastrointestinal services, is essential for optimizing outcomes. Conclusions: Advances in genetic testing and biomarker research are transforming the landscape of hereditary PC management. Early detection and personalized treatment strategies are pivotal in improving survival rates. Ongoing multi-institutional research efforts are crucial for validating biomarkers and developing preventive measures, ultimately aiming to reduce the burden of this aggressive cancer.

30 March 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SRSara Elena Campos Ramírez
Sara Elena Campos Ramírez
AGAlejandro Andrés Gracia
Alejandro Andrés Gracia
CACarmen Blanco Abad
Carmen Blanco Abad
PPPaula Gomila Pons
Paula Gomila Pons
PMPablo Gómez Mugarza
Pablo Gómez Mugarza
VAVicente Alonso-Orduña
Vicente Alonso-Orduña
Background: Therapy using lutetium-177 dotatate (177LU) was approved in Europe for the treatment of advanced neuroendocrine tumors (NETs) in 2017. Since then, it has become part of the strategies in the treatment of NETs, making it now possible to evaluate real-life results. Research Design and Methods: Single-arm, retrospective, multicenter, cohort study of all the patients with metastatic NETs treated with 177LU (four cycles of 200 mCi every 8 weeks) in the two medical centers dedicated to the treatment of NETs from the region of Aragón, Spain, from 2017 to 2024. Descriptive analysis of demographic characteristics, efficacy, and survival analysis were performed using the statistics software Jamovi 2.6.14. Results: Sixty-eight patients were included. The majority were male, and the most frequent primary location was the pancreas. The ORR was 30.9%. The DCR was 88%. The median OS was 47.4 months [95% CI, 25.6–NE]. The median PFS was 26.1 months [95% CI, 18.5–68.3]. High-grade tumors, multiple previous treatments, and pancreatic location presented worse OS. In total, 42.6% presented any grade adverse event (17.2% hematologic, 30.9% GI symptoms). Conclusions: The efficacy of 177LU in our study is like that observed in similar studies. Acceptable tolerance has been shown. Pancreatic tumors, previous treatments, and higher grades demonstrated worse outcomes. The new research line must consider the use of treatment with 177LU in earlier lines for metastatic disease as well as its possible use in local or locally advanced disease.

1 November 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SRSara Elena Campos Ramírez
Sara Elena Campos Ramírez
PMPablo Gómez Mugarza
Pablo Gómez Mugarza
PPPaula Gomila Pons
Paula Gomila Pons
CACarmen Blanco Abad
Carmen Blanco Abad
MLMaría Pilar Felices Lobera
María Pilar Felices Lobera
AOAna María Comín Orce
Ana María Comín Orce
Background: Patients with systemic autoimmune diseases (SAID) are at a higher risk of developing neoplasms, such as solid tumors and hematologic malignancies. Chronic stimulation of the immune system and some treatments for these diseases increase the risk of developing solid tumors. Also, it is known that patients with SAID are usually excluded from clinical trials, but immune checkpoint inhibitors (ICI) are still used in these patients in everyday practice. Objectives: The objective of this article is to review the most up-to-date and robust literature on the use of ICI in patients with SAID for the treatment of solid tumors to obtain information on the efficacy and safety of these drugs in this subgroup of patients. Methods: A literature review was performed through international databases that included PubMed, Medline, Scopus, and Google Scholar. Articles about the use of ICI for solid tumors in patients with SAID were included; the types of articles included were retrospective studies, systematic reviews, and meta-analyses. A summarized descriptive analysis was performed about the efficacy and safety of ICI treatment for the main solid tumors (lung, melanoma, and other cutaneous malignancies, as well as renal and urothelial carcinoma). Conclusions: In general, it seems that ICI treatment is safe in patients with asymptomatic SAID. Close follow-up with a multidisciplinary team should be performed when ICI therapy is prescribed. A substitution of selective immunosuppressants (SIM) in place of nonselective immunosuppressants (NSIM) in asymptomatic patients is recommended before the initiation of ICI.

11 August 2026 in Cancers
Verified
Journal Article
Open access
PDF file
CACarmen Blanco Abad
Carmen Blanco Abad
DDDiego Casas Deza
Diego Casas Deza
FCFátima Mocha Campillo
Fátima Mocha Campillo
NFNatalia Pascual de la Fuente
Natalia Pascual de la Fuente
SESofía Ruffini Egea
Sofía Ruffini Egea
Roberto Pazo-CidRoberto Pazo-Cid
Roberto Pazo-Cid
Background and Aim: Germline testing (GT) is increasingly relevant in pancreatic ductal adenocarcinoma (PDAC) because of therapeutic and familial implications. We evaluated real-world GT uptake, the diagnostic yield of pathogenic/likely pathogenic germline variants (P/LP), and their clinical implications. Methods: We retrospectively evaluated 674 consecutive patients with PDAC. GT was performed using targeted single-gene testing or multigene panels. Survival analyses among patients receiving platinum-based chemotherapy according to P/LP germline variant status in HRR-associated genes were exploratory. Results: Overall, 28.9% of patients underwent GT, increasing to 45.9% in 2021–2025 (p < 0.001). Results were available for 194 patients; 28 (14.4%) harbored P/LP variants, most commonly BRCA2 (4.6%) and ATM (3.1%). P/LP variants were identified in 6.8% of patients who did not meet classical referral criteria. Among the 28 carriers, 12 (42.9%) harbored BRCA1/2 or PALB2, variants with established therapeutic relevance, while eight (28.6%) carried ATM, FANCA, or FANCM, variants with potential therapeutic relevance. Of these 20 patients, 11 (55.0%) received matched therapy, and treatment was modified because of the germline result in six (30.0%). In exploratory analyses, among platinum-treated patients, carriers of P/LP germline variants in HRR-associated genes had longer PFS than non-carriers (23.9 vs. 4.8 months; log-rank p = 0.017), although only six HRR-associated variant carriers were included in this platinum-treated survival analysis. Conclusions: GT remained underused despite increasing implementation. Early systematic GT may identify clinically relevant variants missed by selective referral strategies and inform treatment, genetic counseling, and cascade testing. Survival findings require prospective validation.